Your browser doesn't support javascript.
loading
Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
Lee, Wen Shi; Kristensen, Anne B; Rasmussen, Thomas A; Tolstrup, Martin; Østergaard, Lars; Søgaard, Ole S; Wines, Bruce D; Hogarth, P Mark; Reynaldi, Arnold; Davenport, Miles P; Emery, Sean; Amin, Janaki; Cooper, David A; Kan, Virginia L; Fox, Julie; Gruell, Henning; Parsons, Matthew S; Kent, Stephen J.
Afiliación
  • Lee WS; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Kristensen AB; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Rasmussen TA; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Tolstrup M; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Østergaard L; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Søgaard OS; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Wines BD; Burnet Institute, Melbourne, VIC, Australia.
  • Hogarth PM; Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Reynaldi A; Department of Pathology, The University of Melbourne, Melbourne, VIC, Australia.
  • Davenport MP; Burnet Institute, Melbourne, VIC, Australia.
  • Emery S; Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Amin J; Department of Pathology, The University of Melbourne, Melbourne, VIC, Australia.
  • Cooper DA; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Kan VL; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Fox J; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Gruell H; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Parsons MS; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
  • Kent SJ; Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
J Virol ; 91(15)2017 08 01.
Article en En | MEDLINE | ID: mdl-28539449
ABSTRACT
There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency. A potential barrier is that HIV-1-specific ADCC antibodies decline in patients on long-term antiretroviral therapy (ART) and may not be sufficient to eliminate reactivated latently infected cells. It is not known whether reactivation from latency with latency-reversing agents (LRAs) could provide sufficient antigenic stimulus to boost HIV-1-specific ADCC. We found that treatment with the LRA panobinostat or a short analytical treatment interruption (ATI), 21 to 59 days, was not sufficient to stimulate an increase in ADCC-competent antibodies, despite viral rebound in all subjects who underwent the short ATI. In contrast, a longer ATI, 2 to 12 months, among subjects enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) trial robustly boosted HIV-1 gp120-specific Fc receptor-binding antibodies and ADCC against HIV-1-infected cells in vitro These results show that there is a lag between viral recrudescence and the boosting of ADCC antibodies, which has implications for strategies toward eliminating latently infected cells.IMPORTANCE The "shock and kill" HIV-1 cure strategy aims to reactivate HIV-1 expression in latently infected cells and subsequently eliminate the reactivated cells through immune-mediated killing. Several latency reversing agents (LRAs) have been examined in vivo, but LRAs alone have not been able to achieve HIV-1 remission and prevent viral rebound following analytical treatment interruption (ATI). In this study, we examined whether LRA treatment or ATI can provide sufficient antigenic stimulus to boost HIV-1-specific functional antibodies that can eliminate HIV-1-infected cells. Our study has implications for the antigenic stimulus required for antilatency strategies and/or therapeutic vaccines to boost functional antibodies and assist in eliminating the latent reservoir.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Inmunidad Adaptativa / Citotoxicidad Celular Dependiente de Anticuerpos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Virol Año: 2017 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Inmunidad Adaptativa / Citotoxicidad Celular Dependiente de Anticuerpos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Virol Año: 2017 Tipo del documento: Article País de afiliación: Australia